A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma
Latest Information Update: 26 Sep 2024
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Corticosteroids; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma; Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms ZUMA-7
- Sponsors Kite Pharma
- 19 Sep 2024 Planned End Date changed from 1 Oct 2034 to 1 Nov 2024.
- 15 Aug 2024 This trial has been completed in Sweden, according to European Clinical Trials Database record.
- 08 Jul 2024 This trial has been completed in Germany, according to European Clinical Trials Database record.